Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301

Next Previous
Trial Profile

A Multicenter, Double-blind, Phase 2b/3 Extension Study to Assess the Safety and Efficacy of ABP-671 in Participants With Gout Who Completed the Double-blind Treatment Period in Study ABP-671-301

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 30 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lingdolinurad (Primary) ; Allopurinol
  • Indications Gout
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Atom Bioscience

Most Recent Events

  • 19 Sep 2024 Status changed from recruiting to discontinued, due to redesign of the clinical development program of ABP-671. A new long-term safety study is planned after the completion and analysis of Part 1 of ABP-671-301 (NCT05818085), which will be conducted using the doses selected for the pivotal studies.
  • 03 Mar 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top